Exp Clin Endocrinol Diabetes 1996; 104(1): 67-71
DOI: 10.1055/s-0029-1211424
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients

L. De Marinis, A. Mancini, P. Zuppi, C. Fiumara, G. Conte, L. Sammartano, M. L. Fabrizi, D. Valle*
  • Institute of Endocrinology, the Catholic University School of Medicine, Rome, Italy
  • * Chair of Internal Medicine II, the Catholic University School of Medicine, Rome, Italy
Further Information

Publication History

Publication Date:
15 July 2009 (online)

Summary

In order to gain insight into the neuroendocrine mechanism underlying the paradoxical GH response to TRH in acromegalic patients, we have investigated the effect of an infusion of Naloxone (Nal, 1.6 mg/hr for two hours), on a TRH test performed both in responder (n = 9) and non-responder (n = 5) acromegalic patients. The response of GH, PRL and TSH to TRH injection were evaluated.

NAL did not exert significant variations in the GH response, even if different patterns of GH response during NAL were observed in the group of TRH-responder patients. Similarly, TRH-induced PRL response was not significantly affected by the infusion of an opiate antagonist. On the contrary, a significant inhibition of the TSH response was observed in the group of TRH-responder patients (delta TSH after TRH 4.76 ± 1.11 µU/ ml, after NAL + TRH 2.81 ± 0.99 µU/ml, p < 0.05). No significant effects were observed in the TRH non-responder patients (delta TSH after TRH 4.58 ± 1.44 µU/ml, after NAL + TRH 6.26 ± 3.27 µU/ml). The differences observed in the two groups of patients could be ascribed to a different endogenous somatostatinergic tone and could fournish a prognostic indication in acromegalic patients.